Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Reddy's launches five generics in US

This article was originally published in Scrip

Executive Summary

Dr Reddy's Laboratories launched five generic products in the US last month. These are levetiracetam tablets 250mg, 500mg, 750mg and 1000mg, generic versions of UCB's Keppra tablets; omeprazole capsules 40mg, a generic version of AstraZeneca's Prilosec DR; lamotrigine CD chewable tablets 5mg and 25mg and lamotrigine tablets 25mg, 100mg, 150mg and 200mg, generic versions of GlaxoSmithKline's Lamictal; and divalproex capsules and delayed-release pellets 125mg, a generic version of Abbott's Depakote delayed-release capsules. Dr Reddy's has 69 ANDAs, addressing innovator sales of $47 billion, pending at the US FDA.

You may also be interested in...

Biocon Biologics CEO Makes Surprise Exit

The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.

Prices Plunge As Xarelto Generics Arrive In India

More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.

Dr Reddy’s Wants To Break Into Top Five In India

Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts